Status:
UNKNOWN
Accurate Dosimetry and Biomarkers Improve Survival in HCC Patients Treated With Resin 90 Yttrium (90Y)-Microspheres
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Collaborating Sponsors:
Regina Elena Cancer Institute
Conditions:
HCC
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial involves patients with hepatocellular carcinoma (HCC) diagnosis treated with transarterial radioembolization (TARE) with resin microspheres loaded with 90Y. Patients will be divided in two ...
Detailed Description
The hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. For a large number of patients surgery is not feasible, due to disease multifocality or liver impairment. Several te...
Eligibility Criteria
Inclusion
- hepatocellular carcinoma diagnosis (BCLC stage B or C)
- appropriate liver function (Child-Pugh A or B\<8)
- life expectancy \> 3 months
- bilirubin \< 2.0 ng/ml
- multidisciplinary team consensus to the treatment
- multiphasic CT within 1 month prior to the treatment
- written informed consent
Exclusion
- lung shunt fraction \> 20%
- Child-Pugh score C
- BCLC stage D
- liver impairment
- relevant ascites
- hepatic encephalopathy
- vascular abnormality not allowing proper catheterization
- significant distant metastasis
Key Trial Info
Start Date :
April 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05227482
Start Date
April 10 2018
End Date
December 31 2023
Last Update
February 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138